Back to search results

Testing Mindfulness for Smoking and Alcohol Use in Cancer Survivors

This study is testing a program called Mindfulness-Based Relapse Prevention for Smoking and Alcohol (MBRP-SA) to help cancer survivors quit smoking and reduce heavy drinking. MBRP-SA is a nine-week group program that teaches mindfulness skills to manage cravings and stress. Some participants will also receive nicotine replacement therapy. Others will receive standard support from the Florida Tobacco Quitline. The study wants to see if MBRP-SA is more effective than standard care. To join, you must be at least 18, have a history of cancer, smoke daily, binge drink or drink heavily, want to change your habits, live in Florida, and speak English. Success will be measured by how many people quit smoking and reduce heavy drinking after six months. The study is currently unclear on its recruitment status and plans to enroll 600 people.

Study design
This is an interventional study comparing two behavioral interventions. It aims to enroll 600 participants.
What's involved
Participants will engage in a nine-week group-based mindfulness program or receive support from the Florida Tobacco Quitline. Some will also receive 10 weeks of nicotine replacement therapy.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for six months after treatment to measure smoking abstinence and heavy drinking days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07447635

Testing an MBI for Smoking Cessation and Alcohol Use Among Cancer Survivors

Recruiting
NAAges 18+InterventionalSupportive care
H. Lee Moffitt Cancer Center and Research Institute
~600 participants
Updated 2026-05-18 on ClinicalTrials.gov
What's tested:Mindfulness-Based Relapse Prevention for Smoking and Alcohol (MBRP-SA)Quitline Support

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Biochemically Confirmed 7-Day Point Prevalence Smoking Abstinence
Measured over 6 months post treatment
+1 more outcome measured

Conditions

Smoking Cessation
Alcohol Use

Explore related trials

Alcohol ConsumptionMalignant NeoplasmSmoking Cessation

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Christine Vinci, PhD · PRINCIPAL_INVESTIGATOR · Moffitt Cancer Center

Who to contact

Skye Dougan, MPH
[email protected]
813-745-4376
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

≥18 years old
History of a cancer diagnosis at any point in lifetime
Smoked ≥1 cigarette/day in past month
At least one binge drinking episode in past month or exceeds weekly drinking limits
Motivated to quit smoking and modify alcohol use in next 30 days
Valid home address in Florida
English-speaking, reading, and writing ability

Exclusion

Pregnancy or lactation
Active psychotic disorder
History of severe alcohol withdrawal
Current use of tobacco cessation medication or other treatments to quit smoking
End-of-life or hospice care
Household member already enrolled

What this trial measures

  • Biochemically Confirmed 7-Day Point Prevalence Smoking Abstinence6 months post treatment

    Self-reported no combustible tobacco use in the past 7 days, verified with saliva cotinine \<10 ng/mL.

  • Percent Heavy Drinking Days (Past 4 Weeks)6 months post treatment

    Percentage of days in the past 4 weeks meeting heavy drinking criteria (≥5 drinks for men; ≥4 drinks for women)